Brexpiprazole has low cataleptogenic activity due to balanced 5-HT1A/D2 activity. Dialysis proposes preferential brexpiprazole effect on presynaptic 5-HT1A receptors. Aripiprazole has low cataleptogenic activity, primarily driven by D2 agonism. 5-HT1A agonists reverse catalepsy by preferential effect on presynaptic receptors.